Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia.
Della Starza I, De Novi LA, Santoro A, Salemi D, Spinelli O, Tosi M, Soscia R, Paoloni F, Cappelli LV, Cavalli M, Apicella V, Bellomarino V, Di Lello E, Vitale A, Vignetti M, Fabbiano F, Rambaldi A, Bassan R, Guarini A, Chiaretti S, Foà R. Della Starza I, et al. Among authors: cappelli lv. J Mol Diagn. 2022 Aug;24(8):893-900. doi: 10.1016/j.jmoldx.2022.04.014. Epub 2022 Jun 13. J Mol Diagn. 2022. PMID: 35710027 Free article.
Current and future therapeutic approaches for the treatment of follicular lymphoma.
Pulsoni A, Cappelli LV, Ballotta L, Canichella M, Serrao A, Annechini G, D'Elia GM, Foà R. Pulsoni A, et al. Among authors: cappelli lv. Expert Rev Anticancer Ther. 2018 Sep;18(9):931-941. doi: 10.1080/14737140.2018.1493926. Epub 2018 Jul 16. Expert Rev Anticancer Ther. 2018. PMID: 29972084 Free article. Review.
Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.
Pulsoni A, Della Starza I, Cappelli LV, Tosti ME, Annechini G, Cavalli M, De Novi LA, D'Elia GM, Grapulin L, Guarini A, Del Giudice I, Foà R. Pulsoni A, et al. Among authors: cappelli lv. Br J Haematol. 2020 Jan;188(2):249-258. doi: 10.1111/bjh.16125. Epub 2019 Aug 5. Br J Haematol. 2020. PMID: 31385309 Free article.
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Del Giudice I, Raponi S, Della Starza I, De Propris MS, Cavalli M, De Novi LA, Cappelli LV, Ilari C, Cafforio L, Guarini A, Foà R. Del Giudice I, et al. Among authors: cappelli lv. Front Oncol. 2019 Aug 29;9:689. doi: 10.3389/fonc.2019.00689. eCollection 2019. Front Oncol. 2019. PMID: 31555576 Free PMC article. Review.
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
Raponi S, Ilari C, Della Starza I, Cappelli LV, Cafforio L, Piciocchi A, Arena V, Mariglia P, Mauro FR, Gentile M, Cutrona G, Moia R, Favini C, Morabito F, Rossi D, Gaidano G, Guarini A, Del Giudice I, Foà R. Raponi S, et al. Among authors: cappelli lv. Br J Haematol. 2020 Jun;189(5):853-859. doi: 10.1111/bjh.16434. Epub 2020 Feb 16. Br J Haematol. 2020. PMID: 32064595 Free article.
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia.
Puzzolo MC, Del Giudice I, Peragine N, Mariglia P, De Propris MS, Cappelli LV, Trentin L, Reda G, Cuneo A, Molica S, Piciocchi A, Arena V, Mauro FR, Guarini A, Foà R. Puzzolo MC, et al. Among authors: cappelli lv. Front Oncol. 2021 Apr 15;11:637186. doi: 10.3389/fonc.2021.637186. eCollection 2021. Front Oncol. 2021. PMID: 33937038 Free PMC article.
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia.
Cafforio L, Raponi S, Cappelli LV, Ilari C, Soscia R, De Propris MS, Mariglia P, Rigolin GM, Bardi A, Peragine N, Piciocchi A, Arena V, Mauro FR, Cuneo A, Guarini A, Foa R, Del Giudice I. Cafforio L, et al. Among authors: cappelli lv. Haematologica. 2022 Jan 1;107(1):334-337. doi: 10.3324/haematol.2020.263715. Haematologica. 2022. PMID: 34647439 Free PMC article. No abstract available.
Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.
Cappelli LV, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L, Barcia Duran JG, Zamponi N, Melnick AM, Boccalatte F, Tam W, Elemento O, Chiaretti S, Guarini A, Foà R, Cerchietti L, Rafii S, Inghirami G. Cappelli LV, et al. Blood. 2023 Feb 2;141(5):503-518. doi: 10.1182/blood.2022015414. Blood. 2023. PMID: 35981563 Free PMC article.
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study.
Malfona F, Tanasi I, Piccini M, Papayannidis C, Federico V, Mancini V, Roncoroni E, Todisco E, Bianchi S, Ciotti G, Chiusolo P, Gentile M, Gianfelici V, Giglio F, Malagola M, Mulé A, Saraceni F, Vetro C, Zallio F, Cappelli LV, Pizzolo G, Foà R, Bonifacio M, Chiaretti S. Malfona F, et al. Among authors: cappelli lv. Haematologica. 2024 Mar 1;109(3):988-993. doi: 10.3324/haematol.2023.283684. Haematologica. 2024. PMID: 37794811 Free PMC article. No abstract available.
24 results